www.fdanews.com/articles/70153-crucell-signs-commercial-per-c6-license-agreement-with-singvax
Crucell Signs Commercial PER.C6 License Agreement With SingVax
March 22, 2005
Dutch biotechnology
company Crucell N.V. today announced the signing of a commercial
PER.C6 license agreement with Singapore-based company SingVax Pte Ltd
for the
development and commercialization of new vaccines against Japanese
encephalitis.
Under the agreement, SingVax will focus on the development and
commercialization
of a Japanese encephalitis vaccine for the endemic population as well
as for
travelers to the Asia Pacific region.
PrimeZone